The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...

A compound found in the gut may reduce some of the manifestations of Alzheimer's disease, according to a Northwestern ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A new portable device developed by Rutgers University researchers can detect genetic mutations linked to hereditary ...

The world just got a little closer. The new iGlobal Radio App is now live, offering users a dynamic way to connect with radio ...

The oral presentation summarized meeting its interim results endpoint in from the U.S. multi-site NEXICART-2 clinical trial evaluating NXC-201 in relapsed/refractory AL Amyloidosis with a data ...

The current treatments for relapsed/refractory AL Amyloidosis typically yield less than a 10% complete response rate, highlighting a significant unmet medical need in this patient population.